Development of antiviral therapy for severe acute respiratory syndrome

Antiviral Res. 2005 Jun;66(2-3):81-97. doi: 10.1016/j.antiviral.2005.03.002. Epub 2005 Apr 26.

Abstract

A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / transmission
  • Disease Outbreaks*
  • Drug Design
  • Humans
  • Severe Acute Respiratory Syndrome / drug therapy*
  • Severe Acute Respiratory Syndrome / epidemiology
  • Severe Acute Respiratory Syndrome / prevention & control
  • Severe Acute Respiratory Syndrome / transmission
  • Severe acute respiratory syndrome-related coronavirus / drug effects
  • Severe acute respiratory syndrome-related coronavirus / immunology
  • Viral Vaccines / immunology

Substances

  • Antiviral Agents
  • Viral Vaccines